公开(公告)号：EP2409712A1

公开(公告)日：2012-01-25

申请号：EP10305796.4

申请日：2010-07-19

申请人： International-Drug-Development-Biotech

发明人： Vermot-Desroches, Claudine ,  Vuillermoz, Boris Sébastien

IPC分类号： A61K47/48 ,  C07K16/28

CPC分类号： C07K16/3061 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77

摘要： The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or higher level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.

摘要翻译： 本发明涉及具有相对于野生型Fc区具有特定氨基酸修饰的变体Fc区的抗CD19抗体，其赋予一种或几种有用的效应子功能。 本发明特别涉及包含这种变体Fc区的嵌合，人源化或全人抗CD19抗体。 其有利地涉及具有有趣和有价值的糖基化谱，特别是低岩藻糖水平和/或高寡甘露糖水平和/或更高水平的唾液酸化糖型的抗体。 本发明还涉及这些抗体在治疗，预防或治疗疾病或病症如癌症，特别是B细胞恶性肿瘤和自身免疫疾病中的用途。

公开(公告)号：EP3048116A1

公开(公告)日：2016-07-27

申请号：EP15305079.4

申请日：2015-01-23

申请人： International-Drug-Development-Biotech

发明人： Vermot-Desroches, Claudine ,  Vuillermoz, Boris Sébastien

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2878 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

摘要： The present disclosure relates to binding specifically to the DR5 receptor and that comprise specific CDRs and variations at positions 326, 333 and 396 (Fc region) which may provide to regulate apoptosis potency. The variants have no modified glycan profiles. The present disclosure claims pharmaceutical compositions and the treatment of cancers, autoimmune disease, inflammatory disease or condition, infectious disease, e.g. viral infection and viral disease, neurological disorder.

摘要翻译： 本公开涉及特异性结合DR5受体并且包含特异性CDR和在可能提供调节凋亡效力的位置326,333和396（Fc区））上的变体。 这些变体没有修饰的聚糖谱。 本公开要求药物组合物和治疗癌症，自身免疫疾病，炎性疾病或病症，感染性疾病，例如， 病毒感染和病毒性疾病，神经系统疾病。